Eikon submits EIK1006 application for prostate cancer clinical testing
Published in Diseases!, Drugs development & discovery.
Published October 15, 2026.
Eikon Therapeutics announced on October 15 that it submitted an FDA Investigational New Drug application for EIK1006 in advanced metastatic prostate cancer. The company describes this experimental androgen receptor antagonist as structurally distinct from lutamide-class drugs and designed to target receptor variants associated with treatment resistance.
Evidence limits: This is a company announcement of a submission, not evidence of FDA clearance, treatment approval or patient benefit. Human safety and efficacy remain to be established.
Source: Eikon Therapeutics announcement, October 15, 2026.